Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Dragonfly Therapeutics CPH ApS
APS
In liquidation
Advertising protection
CVR 41557958
Baltorpvej 154, 2750
Ballerup
Forskning og eksperimentel udvikling indenfor bioteknologi
·
NACE 721100
Est. 2020 · 5 years old
16 employees
Monitor
Share
Denmark
/
Companies
/
Forskning og eksperimentel udvikling indenfor bioteknologi
/
Dragonfly Therapeutics CPH ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
11M
22M
34M
45M
39M
2021
26M
2022
EBITDA
DKK millions
10M
8M
5M
3M
0M
8M
2021
8M
0%
2022
Income statement
DKK thousands
Item
2021
2022
Gross profit
38.742
25.842
Staff expenses
-31.006
-18.212
EBITDA
7.527
7.631
Depreciation & amort.
-4.622
-15.564
EBIT
2.904
-7.933
Net financials
-249
-282
Profit before tax
2.655
-8.216
Tax
589
-161
Net profit
2.066
-8.054
Balance sheet
DKK thousands
Item
2021
2022
Total assets
28.800
45.821
Equity
2.106
-5.948
Long-term debt
0
0
Short-term debt
26.533
51.769
Total debt
26.533
51.769
Financial ratios
5-year trend
EBITDA margin (of gross profit)
29.5%
This company
2021
2022
Equity ratio
-13.0%
This company
38.2%
Market median
-134% vs market
2021
2022
Return on equity
-805439000.0%
This company
18.4%
Market median
-4377385970% vs market
2021
2022
Net profit margin (of gross profit)
-31.2%
This company
2021
2022
Asset turnover (of gross profit)
0.56×
This company
2021
2022
Debt / equity
8.70×
This company
0.62×
Market median
-1303% vs market
2021
2022
Annual reports & filings
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2020-07-29 – 2021-12-31
View
PDF
More on Dragonfly Therapeutics CPH ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
